SEC Form 3 · accession 0001628280-26-063097
Gossamer Bio, Inc. · GOSS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory Austin Ciongoli
Director
Period of report
Sep 16, 2026
Accepted (ET)
Sep 22, 2026 · 6:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001728117
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-Funded Warrant (Right to Buy)F1,F2 | $0.0001 | holding | — | — | — | Aug 24, 2026 | — | Series A-1 Preferred Stock | 250 | — | D |
Explanation of responses
- F1The Pre-Funded Warrant has no expiration date and is exercisable immediately. Prior to the Issuer obtaining stockholder approval under applicable Nasdaq rules and regulations in connection with the Issuer's private placement pursuant to which the Pre-Funded Warrants were issued ("Stockholder Approval"), the Pre-Funded Warrants are only exercisable for shares of Series A-1 non-voting convertible preferred stock. Following the Issuer's receipt of Stockholder Approval, the Pre-Funded Warrants are only exercisable for shares of the Issuer's common stock.
- F2Each share of Series A-1 non-voting convertible preferred stock is convertible automatically upon receipt of Stockholder Approval into a number of shares of the Issuer's common stock equal to $1,000 divided by $11.20, pursuant to the terms of the Series A-1 Certificate of Designation and subject to applicable beneficial ownership limitations.